Lindsay M. LaFave (Saunders), PhD

Assistant Professor, Albert Einstein College of Medicine
Lindsay M. Saunders, BS

Lab Phone

646-888-2796

Email

[email protected]

Dissertation

Role of the BAP1/ASXL1 Complex in Malignant Transformation and Therapeutic Response (2015)

Mentor

Ross L. Levine, MD

Start Year

2009

End Year

2016

Education

University of Michigan

Publications

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. (2016) Reply to “Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status”. Nat Med. 22, 578-9.

LaFave LM, Levine RL. (2016)  Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. Nat Med., 22, 20-1.

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. (2015)  Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med., 21, 1344-9. PMCID: PMC4636469.

Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL. (2014)  Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood, 124, 2280-4. PMCID: PMC4183987.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, LaFave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R. (2013) Deletion of Asxl1 results in myelodysplasia and sever developmental defects in vivo. J Exp Med, 210, 2641-2659. PMCID: PMC3832937.

LaFave L, Levine R. (2013) Mining the epigenetic landscape in ALL. Nat Genet, 45, 1269-1270.

Abdel-Wahab O, Adli M, LaFave L, Gao J, Hricik T, Shih A, Pandey S, Patel J, Chung Y, Koche R, Perna F, Zhao X, Taylor J, Park C, Carroll M, Melnick A, Nimer S, Jaffe J, Aifantis I, Bernstein B, Levine R. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell, 22, 180-193. PMCID: PMC3422511.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders L, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert B, Chiosis G, Nimer S, Berstein B, Verstovsek S, Levine R. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 489, 155-159. PMCID: PMC3991463.

LaFave L, Levine R. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci, 33, 574-582.

Dey A, Seshasayee D, Noubade R, French D, Liu J, Chaurushiya M, Kirkpatrick D, Pham V, Lill J, Bakalarski C, Wu J, Phu L, Katavolos P, LaFave L, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine R, Dixit V. (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science, 337, 1541-1546.

Dawson M, Bannister A, Saunders L, Wahab O, Liu F, Nimer S, Levine R, Göttgens B, Kouzarides T, Green A. (2011) Nuclear JAK2. Blood, 118, 6987-6988.

Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE. (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck, 32, 417-26. PMCID: PMC3292176

View a full listing of Lindsay M. LaFave (Saunders)’s journal articles.